JP2021535079A - 代謝性疾患の処置において使用するためのマイクロrnaインヒビター - Google Patents
代謝性疾患の処置において使用するためのマイクロrnaインヒビター Download PDFInfo
- Publication number
- JP2021535079A JP2021535079A JP2020569736A JP2020569736A JP2021535079A JP 2021535079 A JP2021535079 A JP 2021535079A JP 2020569736 A JP2020569736 A JP 2020569736A JP 2020569736 A JP2020569736 A JP 2020569736A JP 2021535079 A JP2021535079 A JP 2021535079A
- Authority
- JP
- Japan
- Prior art keywords
- mir
- fragment
- inhibitor
- nucleic acid
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 title claims description 20
- 229940122938 MicroRNA inhibitor Drugs 0.000 title 1
- 239000012634 fragment Substances 0.000 claims abstract description 152
- 239000003112 inhibitor Substances 0.000 claims abstract description 147
- 108091086215 miR-379 stem-loop Proteins 0.000 claims abstract description 114
- 108091023526 miR-541 stem-loop Proteins 0.000 claims abstract description 114
- 108091007685 MIR541 Proteins 0.000 claims abstract description 109
- 108091079015 miR-379 Proteins 0.000 claims abstract description 109
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 90
- 239000002773 nucleotide Substances 0.000 claims description 89
- 150000007523 nucleic acids Chemical group 0.000 claims description 55
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 40
- 239000002679 microRNA Substances 0.000 claims description 36
- 108091070501 miRNA Proteins 0.000 claims description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 26
- 239000003862 glucocorticoid Substances 0.000 claims description 26
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 14
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- -1 cyclohexene nucleic acid Chemical class 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 11
- 239000004055 small Interfering RNA Substances 0.000 claims description 11
- 206010022489 Insulin Resistance Diseases 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 230000003818 metabolic dysfunction Effects 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 230000002503 metabolic effect Effects 0.000 claims description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 7
- 201000001421 hyperglycemia Diseases 0.000 claims description 7
- 239000002502 liposome Substances 0.000 claims description 7
- 208000014311 Cushing syndrome Diseases 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 6
- 229920002873 Polyethylenimine Polymers 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 6
- 108091060271 Small temporal RNA Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 4
- 238000007385 chemical modification Methods 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 206010025482 malaise Diseases 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- NTPQDQNDQNWGFV-UHFFFAOYSA-N (morpholin-4-ylamino)phosphonic acid Chemical compound OP(O)(=O)NN1CCOCC1 NTPQDQNDQNWGFV-UHFFFAOYSA-N 0.000 claims description 3
- 108091032955 Bacterial small RNA Proteins 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 206010016165 failure to thrive Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108091029810 SaRNA Proteins 0.000 claims 1
- 229940078677 sarna Drugs 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 42
- 239000008103 glucose Substances 0.000 description 42
- 108700011259 MicroRNAs Proteins 0.000 description 35
- 230000005764 inhibitory process Effects 0.000 description 33
- 210000004185 liver Anatomy 0.000 description 29
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 24
- 239000013642 negative control Substances 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 19
- 239000002777 nucleoside Substances 0.000 description 19
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 18
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 15
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 229940029575 guanosine Drugs 0.000 description 14
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 12
- 229940104230 thymidine Drugs 0.000 description 12
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 10
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 9
- 150000003833 nucleoside derivatives Chemical class 0.000 description 9
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 9
- 229940045145 uridine Drugs 0.000 description 9
- 125000003835 nucleoside group Chemical group 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- OLXZPDWKRNYJJZ-RRKCRQDMSA-N 2'-deoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 OLXZPDWKRNYJJZ-RRKCRQDMSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000002212 purine nucleoside Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 150000002972 pentoses Chemical class 0.000 description 4
- 239000002718 pyrimidine nucleoside Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- SPZUXKZZYDALEY-UHFFFAOYSA-N 1-pyrimidin-2-ylethanone Chemical class CC(=O)C1=NC=CC=N1 SPZUXKZZYDALEY-UHFFFAOYSA-N 0.000 description 2
- ICHLNDWMYWZUTG-UHFFFAOYSA-N 2-azido-7h-purine Chemical class [N-]=[N+]=NC1=NC=C2NC=NC2=N1 ICHLNDWMYWZUTG-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000005700 bromopyrimidines Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- LLHRMWHYJGLIEV-UHFFFAOYSA-N desoxy Chemical group COC1=CC(CCN)=CC(OC)=C1C LLHRMWHYJGLIEV-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- SYCUMVXQKYPFDT-DJLDLDEBSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-methoxy-5-methylpyrimidin-2-one Chemical compound C1=C(C)C(OC)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 SYCUMVXQKYPFDT-DJLDLDEBSA-N 0.000 description 1
- MXHRCPNRJAMMIM-ULQXZJNLSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidine-2,4-dione Chemical compound O=C1NC(=O)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 MXHRCPNRJAMMIM-ULQXZJNLSA-N 0.000 description 1
- UTAIYTHAJQNQDW-KQYNXXCUSA-N 1-methylguanosine Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTAIYTHAJQNQDW-KQYNXXCUSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- FPUGCISOLXNPPC-UHFFFAOYSA-N 2'-O-Methyladenosine Natural products COC1C(O)C(CO)OC1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-UHFFFAOYSA-N 0.000 description 1
- OVYNGSFVYRPRCG-UHFFFAOYSA-N 2'-O-Methylguanosine Natural products COC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 OVYNGSFVYRPRCG-UHFFFAOYSA-N 0.000 description 1
- OVYNGSFVYRPRCG-KQYNXXCUSA-N 2'-O-methylguanosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 OVYNGSFVYRPRCG-KQYNXXCUSA-N 0.000 description 1
- HPHXOIULGYVAKW-IOSLPCCCSA-N 2'-O-methylinosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HPHXOIULGYVAKW-IOSLPCCCSA-N 0.000 description 1
- HPHXOIULGYVAKW-UHFFFAOYSA-N 2'-O-methylinosine Natural products COC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 HPHXOIULGYVAKW-UHFFFAOYSA-N 0.000 description 1
- PZJVURYAPQDZOV-VITAEQTISA-N 2-amino-9-[(2s,3r,4s,5r)-2-bromo-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@]1(Br)O[C@H](CO)[C@@H](O)[C@H]1O PZJVURYAPQDZOV-VITAEQTISA-N 0.000 description 1
- VUUFPZIGOAEYHC-UHFFFAOYSA-N 2-bromo-7h-purine Chemical class BrC1=NC=C2NC=NC2=N1 VUUFPZIGOAEYHC-UHFFFAOYSA-N 0.000 description 1
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- NLNBAECVVCECKY-UUOKFMHZSA-N 8-azido-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1N=[N+]=[N-] NLNBAECVVCECKY-UUOKFMHZSA-N 0.000 description 1
- ZDEXANRUPKJZGW-UUOKFMHZSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-8-iodo-3h-purin-6-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1I ZDEXANRUPKJZGW-UUOKFMHZSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- MIKUYHXYGGJMLM-UUOKFMHZSA-N Crotonoside Chemical compound C1=NC2=C(N)NC(=O)N=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MIKUYHXYGGJMLM-UUOKFMHZSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091093073 MiR-134 Proteins 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 108091028076 Mir-127 Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 description 1
- UNUYMBPXEFMLNW-DWVDDHQFSA-N N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine Chemical compound C1=NC=2C(NC(=O)N[C@@H]([C@H](O)C)C(O)=O)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UNUYMBPXEFMLNW-DWVDDHQFSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- PSGWNCVLDUCUCV-UHFFFAOYSA-N bromopurine Chemical compound BrC1=NC=NC2=NC=N[C]12 PSGWNCVLDUCUCV-UHFFFAOYSA-N 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108091090692 miR-337 stem-loop Proteins 0.000 description 1
- 108091032985 miR-382 Proteins 0.000 description 1
- 108091050135 miR-382 stem-loop Proteins 0.000 description 1
- 108091028761 miR-409 stem-loop Proteins 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000006566 systemic energy metabolism Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
(a)miR-379またはその一部もしくは断片のインヒビターおよびmiR-541またはその一部もしくは断片のインヒビター、ならびに/または
(b)miR-379またはその一部もしくは断片の標的部位のインヒビターおよびmiR-541またはその一部もしくは断片の標的部位のインヒビター、ならびに/または
(c)miR-379またはその一部もしくは断片のインヒビターとmiR-541またはその一部もしくは断片の標的部位のインヒビターとの組み合わせ、あるいはmiR-379またはその一部もしくは断片の標的部位のインヒビターとmiR-541またはその一部もしくは断片のインヒビターとの組み合わせ
を含む、組成物に関する。
SEQ ID NO: 1
RNA ホモ・サピエンス(H. sapiens)
miR-379-5p
太字:インヒビターSEQ ID NO: 3に相補的な配列
SEQ ID NO: 2
RNA ホモ・サピエンス
miR-541-5p
太字:インヒビターSEQ ID NO: 4に相補的な配列
SEQ ID NO: 3
DNA人工
miR-379のインヒビター
SEQ ID NO: 4
DNA人工
miR-541のインヒビター
SEQ ID NO: 5
RNA人工
TuDに含まれるmiR-379およびmiR-541に対する阻害配列
1. (a)miR-379またはその一部もしくは断片のインヒビターおよびmiR-541またはその一部もしくは断片のインヒビター;ならびに/または
(b)miR-379またはその一部もしくは断片の標的部位のインヒビターおよびmiR-541またはその一部もしくは断片の標的部位のインヒビター;ならびに/または
(c)miR-379またはその一部もしくは断片のインヒビターとmiR-541またはその一部もしくは断片の標的部位のインヒビターとの組み合わせ、あるいはmiR-379またはその一部もしくは断片の標的部位のインヒビターとmiR-541またはその一部もしくは断片のインヒビターとの組み合わせ
を含む、組成物。
2. 少なくとも1つのmiR-379またはその一部もしくは断片のインヒビターが、miR-379またはその一部もしくは断片に相補的であるかまたはそれにハイブリダイズするヌクレオチド配列を含み、かつ少なくとも1つのmiR-541またはその一部もしくは断片のインヒビターが、miR-541またはその一部もしくは断片に相補的であるかまたはそれにハイブリダイズするヌクレオチド配列を含む、アイテム1の組成物。
3. miR-379の一部が、6個以下のヌクレオチドが置換された、SEQ ID NO: 1に示されるヌクレオチド配列を有し;かつ
miR-541の一部が、8個以下のヌクレオチドが置換された、SEQ ID NO: 2に示されるヌクレオチド配列を有する、
アイテム1または2の組成物。
4. 少なくとも1つのインヒビターが、少なくとも10個のヌクレオチドを含む核酸配列を含む、アイテム1〜3のいずれか一つの組成物。
5. 少なくとも1つのインヒビターが、タフデコイ(Tough Decoy)(TuD)、デコイ、アンチセンスオリゴヌクレオチド、アンチmiR、ブロックmiR、リボザイム、外部ガイド配列(EGS)、オリゴヌクレオチド、低分子干渉RNA(siRNA)、スモールテンポラルRNA(small temporal RNA)(stRNA)、低分子ヘアピン型RNA(shRNA)、低分子RNA誘導型遺伝子活性化(small RNA-induced gene activation)(RNAa)、低分子活性化RNA(small activating RNA)(saRNA)、ロックド核酸(LNA)、アンタゴmir、およびペプチド核酸(PNA)からなる群より選択される、アイテム1〜4のいずれか一つの組成物。
6. 少なくとも1つのインヒビターがタフデコイRNA(TuD)である、アイテム5の組成物。
7. 少なくとも1つのインヒビターが、
N-アセチルガラクトサミン(GalNAc)、ホスホロチオエートDNA(PS)、2'-0-メチルRNA(OMe)、2’-0-メトキシ-エチルRNA(MOE)、ペプチド核酸(PNA)、N3'-P5'-ホスホロアミダート(NP)、2’-フルオロ-アラビノ核酸(FANA)、モルホリノホスホロアミダート(MF)、シクロヘキセン核酸(CeNA)、およびトリサイクルDNA(tc-DNA)
を含む核酸類似体からなる群より選択される核酸配列の化学修飾を含む、アイテム1〜6のいずれか一つの組成物。
8. 少なくとも1つのインヒビターが、アデノ随伴ウイルス(AAV)、レンチウイルスベクター、ポリエチレンイミン(PEI)、カチオン性リポソーム、シリカナノ粒子、PEG化PLGA、および中性脂質からなる群より選択される送達媒体に含まれる、アイテム1〜7のいずれか一つの組成物。
9. 少なくとも1つのインヒビターが、アデノ随伴ウイルス(AAV)に含まれる、アイテム1〜8のいずれか一つの組成物。
10. miR-379またはその一部もしくは断片のインヒビターが、5個以下のヌクレオチドが置換された、SEQ ID NO: 3のヌクレオチド配列を含み;かつ/または
miR-541またはその一部もしくは断片のインヒビターが、5個以下のヌクレオチドが置換された、SEQ ID NO: 4のヌクレオチド配列を含む、
アイテム1〜9のいずれか一つの組成物。
11. 同一分子上にmiR-379またはその一部もしくは断片のインヒビターおよびmiR-541またはその一部もしくは断片のインヒビターを含む、組成物であって、該分子が、miR-379またはその一部もしくは断片に相補的であるかまたはそれにハイブリダイズするヌクレオチド配列、およびmiR-541またはその一部もしくは断片に相補的であるかまたはそれにハイブリダイズするヌクレオチド配列を含む、アイテム1〜10のいずれか一つの組成物。
12. 前記インヒビターが、10個以下のヌクレオチドが置換された、SEQ ID NO: 5のヌクレオチド配列を含む、アイテム11の組成物。
13. 薬学的組成物である、アイテム1〜12のいずれか一つの組成物。
14. 代謝性疾患、代謝障害に関連する疾患、および/またはがんの処置または予防に使用するための、アイテム1〜13のいずれか一つの組成物。
15. 代謝性疾患または代謝障害に関連する疾患が、グルココルチコイドホルモン誘発代謝機能不全、肥満、糖尿病、糖尿肥満(diabesity)、メタボリックシンドローム、インスリン抵抗性、高血糖、(全身性)脂質代謝異常、クッシング症候群、グルココルチコイド(GC)処置または過剰なGCに付随するまたはそれによって引き起こされる有害作用または副作用、アテローム動脈硬化症、心疾患、脳卒中、(がん性)悪液質、成長不全、脂肪肝、NASH、および肝線維症からなる群より選択される、アイテム14の組成物。
Claims (15)
- (a)miR-379またはその一部もしくは断片のインヒビターおよびmiR-541またはその一部もしくは断片のインヒビター;ならびに/または
(b)miR-379またはその一部もしくは断片の標的部位のインヒビターおよびmiR-541またはその一部もしくは断片の標的部位のインヒビター;ならびに/または
(c)miR-379またはその一部もしくは断片のインヒビターとmiR-541またはその一部もしくは断片の標的部位のインヒビターとの組み合わせ、あるいはmiR-379またはその一部もしくは断片の標的部位のインヒビターとmiR-541またはその一部もしくは断片のインヒビターとの組み合わせ
を含む、組成物。 - 少なくとも1つのmiR-379またはその一部もしくは断片のインヒビターが、miR-379またはその一部もしくは断片に相補的であるかまたはそれにハイブリダイズするヌクレオチド配列を含み、かつ少なくとも1つのmiR-541またはその一部もしくは断片のインヒビターが、miR-541またはその一部もしくは断片に相補的であるかまたはそれにハイブリダイズするヌクレオチド配列を含む、請求項1記載の組成物。
- miR-379の一部が、6個以下のヌクレオチドが置換された、SEQ ID NO: 1に示されるヌクレオチド配列を有し;かつ
miR-541の一部が、8個以下のヌクレオチドが置換された、SEQ ID NO: 2に示されるヌクレオチド配列を有する、
請求項1または2記載の組成物。 - 少なくとも1つのインヒビターが、少なくとも10個のヌクレオチドを含む核酸配列を含む、請求項1〜3のいずれか一項記載の組成物。
- 少なくとも1つのインヒビターが、タフデコイ(Tough Decoy)(TuD)、デコイ、アンチセンスオリゴヌクレオチド、アンチmiR、ブロックmiR、リボザイム、外部ガイド配列(EGS)、オリゴヌクレオチド、低分子干渉RNA(siRNA)、スモールテンポラルRNA(small temporal RNA)(stRNA)、低分子ヘアピン型RNA(shRNA)、低分子RNA誘導型遺伝子活性化(small RNA-induced gene activation)(RNAa)、低分子活性化RNA(small activating RNA)(saRNA)、ロックド核酸(LNA)、アンタゴmir、およびペプチド核酸(PNA)からなる群より選択される、請求項1〜4のいずれか一項記載の組成物。
- 少なくとも1つのインヒビターがタフデコイRNA(TuD)である、請求項5記載の組成物。
- 少なくとも1つのインヒビターが、
N-アセチルガラクトサミン(GalNAc)、ホスホロチオエートDNA(PS)、2'-0-メチルRNA(OMe)、2’-0-メトキシ-エチルRNA(MOE)、ペプチド核酸(PNA)、N3'-P5'-ホスホロアミダート(NP)、2’-フルオロ-アラビノ核酸(FANA)、モルホリノホスホロアミダート(MF)、シクロヘキセン核酸(CeNA)、およびトリサイクルDNA(tc-DNA)
を含む核酸類似体からなる群より選択される核酸配列の化学修飾を含む、請求項1〜6のいずれか一項記載の組成物。 - 少なくとも1つのインヒビターが、アデノ随伴ウイルス(AAV)、レンチウイルスベクター、ポリエチレンイミン(PEI)、カチオン性リポソーム、シリカナノ粒子、PEG化PLGA、および中性脂質からなる群より選択される送達媒体に含まれる、請求項1〜7のいずれか一項記載の組成物。
- 少なくとも1つのインヒビターが、アデノ随伴ウイルス(AAV)に含まれる、請求項1〜8のいずれか一項記載の組成物。
- miR-379またはその一部もしくは断片のインヒビターが、5個以下のヌクレオチドが置換された、SEQ ID NO: 3のヌクレオチド配列を含み;かつ/または
miR-541またはその一部もしくは断片のインヒビターが、5個以下のヌクレオチドが置換された、SEQ ID NO: 4のヌクレオチド配列を含む、
請求項1〜9のいずれか一項記載の組成物。 - 同一分子上にmiR-379またはその一部もしくは断片のインヒビターおよびmiR-541またはその一部もしくは断片のインヒビターを含む、組成物であって、該分子が、miR-379またはその一部もしくは断片に相補的であるかまたはそれにハイブリダイズするヌクレオチド配列、およびmiR-541またはその一部もしくは断片に相補的であるかまたはそれにハイブリダイズするヌクレオチド配列を含む、請求項1〜10のいずれか一項記載の組成物。
- 前記インヒビターが、10個以下のヌクレオチドが置換された、SEQ ID NO: 5のヌクレオチド配列を含む、請求項11記載の組成物。
- 薬学的組成物である、請求項1〜12のいずれか一項記載の組成物。
- 代謝性疾患、代謝障害に関連する疾患、および/またはがんの処置または予防に使用するための、請求項1〜13のいずれか一項記載の組成物。
- 代謝性疾患または代謝障害に関連する疾患が、グルココルチコイドホルモン誘発代謝機能不全、肥満、糖尿病、糖尿肥満(diabesity)、メタボリックシンドローム、インスリン抵抗性、高血糖、(全身性)脂質代謝異常、クッシング症候群、グルココルチコイド(GC)処置または過剰なGCに付随するまたはそれによって引き起こされる有害作用または副作用、アテローム動脈硬化症、心疾患、脳卒中、(がん性)悪液質、成長不全、脂肪肝、NASH、および肝線維症からなる群より選択される、請求項14記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024037853A JP2024073525A (ja) | 2018-09-11 | 2024-03-12 | 代謝性疾患の処置において使用するためのマイクロrnaインヒビター |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU100927 | 2018-09-11 | ||
LULU100927 | 2018-09-11 | ||
PCT/EP2019/074056 WO2020053186A1 (en) | 2018-09-11 | 2019-09-10 | Microrna inhibitors for use in treating metabolic diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024037853A Division JP2024073525A (ja) | 2018-09-11 | 2024-03-12 | 代謝性疾患の処置において使用するためのマイクロrnaインヒビター |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021535079A true JP2021535079A (ja) | 2021-12-16 |
Family
ID=63998726
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020569736A Pending JP2021535079A (ja) | 2018-09-11 | 2019-09-10 | 代謝性疾患の処置において使用するためのマイクロrnaインヒビター |
JP2024037853A Pending JP2024073525A (ja) | 2018-09-11 | 2024-03-12 | 代謝性疾患の処置において使用するためのマイクロrnaインヒビター |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024037853A Pending JP2024073525A (ja) | 2018-09-11 | 2024-03-12 | 代謝性疾患の処置において使用するためのマイクロrnaインヒビター |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210254067A1 (ja) |
EP (1) | EP3850099A1 (ja) |
JP (2) | JP2021535079A (ja) |
CN (1) | CN112654705A (ja) |
CA (1) | CA3103175A1 (ja) |
WO (1) | WO2020053186A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111228291B (zh) * | 2020-03-20 | 2020-10-02 | 军事科学院军事医学研究院环境医学与作业医学研究所 | miR-541在制备抗神经元细胞缺氧损伤药物中的应用及药物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015063081A2 (en) * | 2013-10-29 | 2015-05-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Micrornas modulating the effect of glucocorticoid signaling |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
WO2014074874A1 (en) * | 2012-11-09 | 2014-05-15 | Regents Of The University Of Minnesota | Osteosarcoma diagnostic and prognostic methods |
RU2020140209A (ru) * | 2014-10-21 | 2021-01-25 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
CN106267207A (zh) * | 2015-06-05 | 2017-01-04 | 昆山彭济凯丰生物科技有限公司 | 通过miR-96进行减肥、降血糖和降血脂的方法和药物及其应用 |
WO2019102268A1 (en) * | 2017-11-22 | 2019-05-31 | Mesoblast International Sarl | Cellular compositions and methods of treatment i |
-
2019
- 2019-09-10 CA CA3103175A patent/CA3103175A1/en active Pending
- 2019-09-10 EP EP19780152.5A patent/EP3850099A1/en active Pending
- 2019-09-10 US US17/251,803 patent/US20210254067A1/en active Pending
- 2019-09-10 CN CN201980058818.XA patent/CN112654705A/zh active Pending
- 2019-09-10 WO PCT/EP2019/074056 patent/WO2020053186A1/en unknown
- 2019-09-10 JP JP2020569736A patent/JP2021535079A/ja active Pending
-
2024
- 2024-03-12 JP JP2024037853A patent/JP2024073525A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015063081A2 (en) * | 2013-10-29 | 2015-05-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Micrornas modulating the effect of glucocorticoid signaling |
Non-Patent Citations (2)
Title |
---|
CELL DEATH & DISEASE, vol. Vol.5, e.1171, JPN6023010514, 2014, pages 1 - 10, ISSN: 0005014559 * |
THE EMBO JOURNAL, vol. 34, JPN6023010512, 2015, pages 344 - 360, ISSN: 0005014558 * |
Also Published As
Publication number | Publication date |
---|---|
CN112654705A (zh) | 2021-04-13 |
JP2024073525A (ja) | 2024-05-29 |
CA3103175A1 (en) | 2020-03-19 |
EP3850099A1 (en) | 2021-07-21 |
WO2020053186A1 (en) | 2020-03-19 |
US20210254067A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3354734B1 (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif | |
AU2012322788B2 (en) | Micrornas in neurodegenerative disorders | |
EP2208499A1 (en) | Nucleic acid capable of regulating the proliferation of cell | |
EP2298359A1 (en) | Nucleic acid capable of controlling degranulation of mast cell | |
EP2683411B1 (en) | Methods of using microrna-26a to promote angiogenesis | |
JP2024073525A (ja) | 代謝性疾患の処置において使用するためのマイクロrnaインヒビター | |
US10612020B2 (en) | Artificial mimic miRNA for controlling gene expression, and use of same | |
Tan et al. | MicroRNA-based therapy in pain medicine: Current progress and future prospects | |
Wu et al. | MiRNAs in human cancers: the diagnostic and therapeutic implications | |
KR20150036140A (ko) | 마이크로RNAs의 MIR-15 패밀리의 억제제 | |
Durso et al. | Chemical modifications in the seed region of miRNAs 221/222 increase the silencing performances in gastrointestinal stromal tumor cells | |
US20160355804A1 (en) | Modulation of microrna-138 for the treatment of bone loss | |
EP3647423A1 (en) | HETERO DOUBLE-STRANDED antimiR | |
EP3928799A1 (en) | Optimal ps modification pattern for heteronucleic acids | |
Zhou et al. | Role of the AKT pathway in microRNA expression of human U251 glioblastoma cells Retraction in/10.3892/ijo. 2023.5597 | |
WO2014053014A1 (en) | Modulation of rna activity and vascular permeability | |
EP2175023A1 (en) | Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA | |
CN116096420A (zh) | 利用miR-33b抑制物质的动脉瘤的预防或治疗 | |
CN102199603B (zh) | 多靶位干扰rna分子及其应用 | |
EP4331606A1 (en) | Prevention or treatment of myopathy using mir-33b inhibitor | |
WO2023127848A1 (ja) | Ebv関連疾患を標的とする核酸医薬 | |
Jian et al. | RNA therapy: Are we using the right molecules? | |
WO2017050848A1 (en) | Nucleic acid molecules with enhanced activity | |
EP2907874A1 (en) | MiR-21-3p inhibitors in skin disorders | |
WO2011010737A1 (ja) | マイクロrna切断用のガイド核酸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210303 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230316 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230914 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20231027 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240312 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240322 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240416 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240422 |